Maria Beatriz Duran-Alonso

Dr. Maria Beatriz Duran-Alonso


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2009 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
AWAshwin Woodhoo
Ashwin Woodhoo
MDMaria Beatriz Duran-Alonso
Maria Beatriz Duran-Alonso
ADAnna Droggiti
Anna Droggiti
MTMark Turmaine
Mark Turmaine
MDMaurizio D'Antonio
Maurizio D'Antonio
KJKristján R Jessen
Kristján R Jessen
Although the role of Notch signaling in CNS glial development is well established, its participation in peripheral glial development is still unclear. This paper shows that Notch signaling regulates the differentiation of Schwann cell precursors and the proliferation of Schwann cells, and acts as a break on myelination of peripheral nerves. Notch signaling is central to vertebrate development, and analysis of Notch has provided important insights into pathogenetic mechanisms in the CNS and many other tissues. However, surprisingly little is known about the role of Notch in the development and pathology of Schwann cells and peripheral nerves. Using transgenic mice and cell cultures, we found that Notch has complex and extensive regulatory functions in Schwann cells. Notch promoted the generation of Schwann cells from Schwann cell precursors and regulated the size of the Schwann cell pool by controlling proliferation. Notch inhibited myelination, establishing that myelination is subject to negative transcriptional regulation that opposes forward drives such as Krox20. Notably, in the adult, Notch dysregulation resulted in demyelination; this finding identifies a signaling pathway that induces myelin breakdown in vivo. These findings are relevant for understanding the molecular mechanisms that control Schwann cell plasticity and underlie nerve pathology, including demyelinating neuropathies and tumorigenesis.

27 February 2006 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
TTamara Lah
Tamara Lah
MDMaria Beatriz Duran-Alonso
Maria Beatriz Duran-Alonso
CNCornelis Jf Van Noorden
Cornelis Jf Van Noorden
The activity of a set of peptidases (proteases) involved in cancer progression is collectively known as the cancer ‘degradome’. Invasion and metastasis were initially considered as late events in cancer development and the processes in which proteases were involved. However, recent studies indicate that invasion and metastasis are not late events, but can occur during early stages as well. Moreover, other processes occurring in various stages of cancer progression are also protease-dependent, such as (upregulation of) cell proliferation, (downregulation of) apoptosis, involvement of white blood cells, angiogenesis and induction of multi-drug resistance. Proteolytic activity in tumours is regulated in a complex manner, as both genetically unstable cancer cells and stable stromal cells, such as fibroblasts, endothelial cells and inflammatory cells, are involved. In vitro studies and studies using animal models have clearly shown protease dependency of many processes in carcinogenesis. However, clinical tria...

1 March 2010 in Cancer Letters
Verified
Journal Article
Closed access
SKSaša Kenig
Saša Kenig
MDMaria Beatriz Duran-Alonso
Maria Beatriz Duran-Alonso
MMMargareta M. Mueller
Margareta M. Mueller
TLTamara T. Lah
Tamara T. Lah

20 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MIMasaaki Ishikawa
Masaaki Ishikawa
NGNadia García-Mateo
Nadia García-Mateo
AČAlen Čusak
Alen Čusak
ILIris López-Hernández
Iris López-Hernández
MFMarta Fernández-Martínez
Marta Fernández-Martínez
MDMaria Beatriz Duran-Alonso
Maria Beatriz Duran-Alonso
Spread of antimicrobial resistance and shortage of novel antibiotics have led to an urgent need for new antibacterials. Although aminoglycoside antibiotics (AGs) are very potent anti-infectives, their use is largely restricted due to serious side-effects, mainly nephrotoxicity and ototoxicity. We evaluated the ototoxicity of various AGs selected from a larger set of AGs on the basis of their strong antibacterial activities against multidrug-resistant clinical isolates of the ESKAPE panel: gentamicin, gentamicin C1a, apramycin, paromomycin and neomycin. Following local round window application, dose-dependent effects of AGs on outer hair cell survival and compound action potentials showed gentamicin C1a and apramycin as the least toxic. Strikingly, although no changes were observed in compound action potential thresholds and outer hair cell survival following treatment with low concentrations of neomycin, gentamicin and paromomycin, the number of inner hair cell synaptic ribbons and the compound action potential amplitudes were reduced. This indication of hidden hearing loss was not observed with gentamicin C1a or apramycin at such concentrations. These findings identify the inner hair cells as the most vulnerable element to AG treatment, indicating that gentamicin C1a and apramycin are promising bases for the development of clinically useful antibiotics.

13 May 2009 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
BGBoris Gole
Boris Gole
MDMaria Beatriz Duran-Alonso
Maria Beatriz Duran-Alonso
VDVincenc Dolenc
Vincenc Dolenc
TLTamara Lah
Tamara Lah

1 May 2003 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
DPDavid B Parkinson
David B Parkinson
SDSarah Dickinson
Sarah Dickinson
ABAmbily Bhaskaran
Ambily Bhaskaran
MKMatthew T Kinsella
Matthew T Kinsella
PBPeter J Brophy
Peter J Brophy
KJKristjan R Jessen
Kristjan R Jessen